{
    "paper_id": "PMC7211081",
    "metadata": {
        "title": "British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic",
        "authors": [
            {
                "first": "Nicholas",
                "middle": [
                    "A"
                ],
                "last": "Kennedy",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Gareth-Rhys",
                "middle": [],
                "last": "Jones",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Christopher",
                "middle": [
                    "A"
                ],
                "last": "Lamb",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Richard",
                "middle": [],
                "last": "Appleby",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Ian",
                "middle": [],
                "last": "Arnott",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "R",
                "middle": [
                    "Mark"
                ],
                "last": "Beattie",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Stuart",
                "middle": [],
                "last": "Bloom",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Alenka",
                "middle": [
                    "J"
                ],
                "last": "Brooks",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Rachel",
                "middle": [],
                "last": "Cooney",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Robin",
                "middle": [
                    "J"
                ],
                "last": "Dart",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Cathryn",
                "middle": [],
                "last": "Edwards",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Aileen",
                "middle": [],
                "last": "Fraser",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Daniel",
                "middle": [
                    "R"
                ],
                "last": "Gaya",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Subrata",
                "middle": [],
                "last": "Ghosh",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Kay",
                "middle": [],
                "last": "Greveson",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Richard",
                "middle": [],
                "last": "Hansen",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Ailsa",
                "middle": [],
                "last": "Hart",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "A",
                "middle": [
                    "Barney"
                ],
                "last": "Hawthorne",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Bu'Hussain",
                "middle": [],
                "last": "Hayee",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Jimmy",
                "middle": [
                    "K"
                ],
                "last": "Limdi",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Charles",
                "middle": [
                    "D"
                ],
                "last": "Murray",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Gareth",
                "middle": [
                    "C"
                ],
                "last": "Parkes",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Miles",
                "middle": [],
                "last": "Parkes",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Kamal",
                "middle": [],
                "last": "Patel",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Richard",
                "middle": [
                    "C"
                ],
                "last": "Pollok",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Nick",
                "middle": [],
                "last": "Powell",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Chris",
                "middle": [
                    "S"
                ],
                "last": "Probert",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Tim",
                "middle": [],
                "last": "Raine",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Shaji",
                "middle": [],
                "last": "Sebastian",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Christian",
                "middle": [],
                "last": "Selinger",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Philip",
                "middle": [
                    "J"
                ],
                "last": "Smith",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Catherine",
                "middle": [],
                "last": "Stansfield",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Lisa",
                "middle": [],
                "last": "Younge",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "James",
                "middle": [
                    "O"
                ],
                "last": "Lindsay",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Peter",
                "middle": [
                    "M"
                ],
                "last": "Irving",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Charlie",
                "middle": [
                    "W"
                ],
                "last": "Lees",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "Inflammatory bowel disease (IBD), comprising Crohn\u2019s disease (CD) and ulcerative colitis (UC), is a condition in which the gastrointestinal immune system responds inappropriately. IBD is therefore often treated with immunosuppressing medications to control inflammation and prevent \u2018flares\u2019, a worsening of symptoms, which may be unpredictable.",
            "cite_spans": [],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "While it is known that 0.8% of people in the UK currently have IBD (approximately 524 000 patients), only 44% have been to a clinic in the past 3 years1 2. There will be many patients who are worried about the effect of the coronavirus pandemic (SARS-CoV-2 or COVID-19 disease) on their IBD and vice versa, many of whom will be unknown to secondary care.",
            "cite_spans": [
                {
                    "start": 151,
                    "end": 154,
                    "mention": "1 2",
                    "ref_id": "BIBREF0"
                }
            ],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "During the COVID-19 outbreak, we will do everything we can to keep our IBD patients safe. The greatest risks relate not only to the infection itself, but also the emergency reorganisation of hospital and general practice services to deal with the pandemic. This will result in significant changes to routine IBD services. A combined approach covering both primary and secondary care is therefore required to keep vulnerable patients with IBD out of hospital as much as possible.",
            "cite_spans": [],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "Insights from Hubei, China and from Italy suggest hospital attendance for non-COVID-19 illness may provide a reservoir for further spread of infection. However, alterations to the way we deliver IBD care in the UK must be balanced against the risks of under treated, active IBD. Importantly, patients with active IBD are likely to have a higher risk of infection both in the community and during inpatient care, even in the absence of immunosuppressive treatment.3 Therefore, it is of paramount importance to control intestinal inflammation in IBD to prevent adverse outcomes.",
            "cite_spans": [
                {
                    "start": 463,
                    "end": 464,
                    "mention": "3",
                    "ref_id": "BIBREF14"
                }
            ],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "The impact of immunosuppression on the severity of COVID-19 disease remains unclear. Data reported from 1099 Chinese patients with COVID-19 did not observe immunodeficiency as a risk factor for severe disease (defined according to the American Thoracic Society guidelines for community acquired pneumonia).4 The currently understood predictors associated with COVID-19 mortality at the time of hospital admission are older age (OR 1.1; 95% CI 1.03 to 1.17 per year increase), higher sequential organ failure assessment score (OR 5.65; 95% CI 2.61 to 12.23) and d-dimer >1 \u00b5g/mL (OR 18.42; 95% CI 2.64 to 128.55).5 However, smoking, comorbidity, particularly hypertension, vascular disease, diabetes and male sex have been associated with poor outcome.4\u20139 Prolonged illness and complications from respiratory infection are perhaps more common when non-steroidal anti-inflammatory drugs (NSAIDs) are used, but no data in COVID-19 currently exist.10 11 Given NSAIDs have also been implicated in IBD flare, paracetamol is advocated as firstline analgesia/antipyretic.12\n",
            "cite_spans": [
                {
                    "start": 306,
                    "end": 307,
                    "mention": "4",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 612,
                    "end": 613,
                    "mention": "5",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 751,
                    "end": 754,
                    "mention": "4\u20139",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 944,
                    "end": 949,
                    "mention": "10 11",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 1063,
                    "end": 1065,
                    "mention": "12",
                    "ref_id": "BIBREF3"
                }
            ],
            "section": "COVID-19 disease and IBD",
            "ref_spans": []
        },
        {
            "text": "At the time of writing, the Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE)-IBD registry has reported 239 (54% male) cases of COVID-19 in IBD patients (137 CD, 94 UC, 5 IBD unclassified), of whom 64 were hospitalised and 11 patients died.13 Seven patients underwent ventilation. Among the 11 patients who died, a range of medications were seen; five patients were receiving mesalazine alone or no therapy, although all were aged 69 years or older; four were receiving steroids alone or in combination; and the youngest patient who died was 33 years and was receiving combination therapy with adalimumab, azathioprine and prednisolone.13 The British Society of Gastroenterology (BSG), in line with the International Organisation for the Study of IBD and the European Crohn\u2019s and Colitis Organisation, recommend that patients with IBD do not routinely stop their medication to prevent infection or adverse outcome with COVID-19.14 15\n",
            "cite_spans": [
                {
                    "start": 265,
                    "end": 267,
                    "mention": "13",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 661,
                    "end": 663,
                    "mention": "13",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 953,
                    "end": 958,
                    "mention": "14 15",
                    "ref_id": "BIBREF5"
                }
            ],
            "section": "COVID-19 disease and IBD",
            "ref_spans": []
        },
        {
            "text": "'Social distancing' (https://www.gov.uk/government/publications/covid-19-guidance-on-social-distancing-and-for-vulnerable-people/guidance-on-social-distancing-for-everyone-in-the-uk-and-protecting-older-people-and-vulnerable-adults) and 'shielding' (https://www.gov.uk/government/publications/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19) are measures to reduce spread within the population and to protect high risk groups. These are also an understandable source of anxiety for patients with IBD.16\n",
            "cite_spans": [
                {
                    "start": 612,
                    "end": 614,
                    "mention": "16",
                    "ref_id": "BIBREF7"
                }
            ],
            "section": "COVID-19 disease and IBD",
            "ref_spans": []
        },
        {
            "text": "On behalf of the BSG, a UK-wide IBD COVID-19 Working Group has been established and has defined patient risk as highest, moderate and lowest for COVID-19 related poor outcome (see table 1 and below for justification of groupings). Patients classified as at highest risk, correspond to group 5 in the UK government\u2019s instruction to undergo \u2018shielding\u2019, the most stringent form of isolation. The moderate group are recommended to be even stricter at following the government\u2019s instructions regarding social distancing. Note that all patients should still attend for infusions of biologics, irrespective of risk stratification.",
            "cite_spans": [],
            "section": "COVID-19 disease and IBD",
            "ref_spans": [
                {
                    "start": 180,
                    "end": 187,
                    "mention": "table 1",
                    "ref_id": "TABREF0"
                }
            ]
        },
        {
            "text": "The UK Department of Health has requested patient contact details from local secondary care IBD services for those that meet the highest risk. A pragmatic approach to identify individuals within the highest risk group has been adopted:",
            "cite_spans": [],
            "section": "COVID-19 disease and IBD",
            "ref_spans": []
        },
        {
            "text": "The self-identification tool (point 3 above) was developed using the information in table 1 in partnership with the IBD Registry as a pragmatic solution to obtain up to date information from UK patients with IBD and maximise the ability to identify patients in the highest risk group. Early identification and intervention (shielding education) to 318 Chinese IBD patients in Hubei at risk of COVID-19 was well received by patients and may have protected them from infection, with none of them reporting infection, as of 28 February 2020.17\n",
            "cite_spans": [
                {
                    "start": 538,
                    "end": 540,
                    "mention": "17",
                    "ref_id": "BIBREF8"
                }
            ],
            "section": "COVID-19 disease and IBD",
            "ref_spans": [
                {
                    "start": 84,
                    "end": 91,
                    "mention": "table 1",
                    "ref_id": "TABREF0"
                }
            ]
        },
        {
            "text": "At the time of writing, there is a lot of activity at UK government level around the wearing of masks by the general population in public spaces and hospitals. The BSG recommends members of the public to follow the most up to date advice from the government with respect to this.",
            "cite_spans": [],
            "section": "COVID-19 disease and IBD",
            "ref_spans": []
        },
        {
            "text": "Most IBD patients will fall into the moderate or lowest risk groups. Defining a \u2018highest risk\u2019 group is not exact, with little or no evidence specific to COVID-19. The grouping has therefore been determined following extensive discussion among UK IBD specialists with input from international colleagues. Based on the current evidence, we understand increasing age, heart disease, diabetes and hypertension are the among the greatest risk factors for poor outcome in COVID-19.4\u20139 As such, priority has been given to these factors alongside medications, other than individuals on high dose steroids (table 1 and below). Where risk is primarily determined by IBD (patient and treatment factors), we recognise this is a dynamic process\u2014that is, patients may move between risk categories over the duration of the pandemic.",
            "cite_spans": [
                {
                    "start": 476,
                    "end": 479,
                    "mention": "4\u20139",
                    "ref_id": "BIBREF15"
                }
            ],
            "section": "COVID-19 disease and IBD",
            "ref_spans": [
                {
                    "start": 599,
                    "end": 606,
                    "mention": "table 1",
                    "ref_id": "TABREF0"
                }
            ]
        },
        {
            "text": "This is a very busy time for clinical teams with redeployment in order to manage the COVID-19 pandemic. We have therefore aimed for simple clear messages wherever possible. For this reason, we have deliberately not provided a drug by drug description of clearance, and recommend it is 3 months after cessation of a drug therapy before a patient changes risk category. In part, this is to discourage the practice of stopping drugs purely to switch risk category. The exception is steroids, which is covered explicitly in the grid. As a working group, we have had some discussion about tofacitinib which has a much shorter half-life; in this case, we advise clinician discretion regarding the time point at which cessation impacts on risk categorisation.",
            "cite_spans": [],
            "section": "COVID-19 disease and IBD",
            "ref_spans": []
        },
        {
            "text": "We wish to strongly emphasise:",
            "cite_spans": [],
            "section": "COVID-19 disease and IBD",
            "ref_spans": []
        },
        {
            "text": "General advice for all IBD patients is provided in box 1.",
            "cite_spans": [],
            "section": "COVID-19 disease and IBD",
            "ref_spans": []
        },
        {
            "text": "To manage and support patients with IBD when outpatient clinics are being converted to telephone review, the minimum service provision needs to include a telephone/email helpline to support patients having disease flares and to answer queries regarding immunosuppressant/biologics management. Ideally, provision should be made for one member of the nursing team to work from home to ensure this is maintained, with appropriate senior review to support the clinical decision making process. This would reduce the burden on both primary and secondary care, in particular the accident and emergency department. This should be supported with capacity for patients to have urgent review if needed in a \u2018safe clinic\u2019.",
            "cite_spans": [],
            "section": "IBD nurse phone and email helpline ::: Changes to current primary and secondary care practices",
            "ref_spans": []
        },
        {
            "text": "Patients are being asked to keep taking their usual IBD therapy. If patients stop taking their medications without discussing it with their clinical team first, there is a risk of disease flare. Active disease is associated with an increased risk of infection, exposure to steroids (increased risk from infection), hospitalisation and major surgery.3 18\n",
            "cite_spans": [
                {
                    "start": 349,
                    "end": 353,
                    "mention": "3 18",
                    "ref_id": "BIBREF14"
                }
            ],
            "section": "IBD nurse phone and email helpline ::: Changes to current primary and secondary care practices",
            "ref_spans": []
        },
        {
            "text": "Conduct clinical appointments by telephone or a formal telemedicine system where possible. Routine bloods may be deferred until the situation has improved, depending on local capacity. Access to faecal calprotectin (FC) testing, a potential alternative to endoscopy, may become limited due to the presence of virus in the stool. If accessible, consider introduction of point of care calprotectin testing. FC point of care kits could be most effectively issued to high risk patients at a new patient/flare clinic or on discharge from hospital (sampling every 2\u20133 months depending on capacity). Given the limited access to endoscopic disease assessment, the combination of FC and clinical disease scores (eg, partial Mayo/Simple Clinical Colitis Activity Index, Paediatric Ulcerative Colitis Activity Index, Harvey\u2013Bradshaw index or weighted Paediatric Crohn's Disease Activity Index) may help to guide treatment decisions more objectively.",
            "cite_spans": [],
            "section": "Outpatient clinics ::: Changes to current primary and secondary care practices",
            "ref_spans": []
        },
        {
            "text": "In line with the Joint Advisory Group/BSG endoscopy guidance released on 26 March 2020, all non-emergency endoscopy should stop immediately. Careful case by case discussion will need to be given to decide the timing of diagnostic endoscopy for the most urgent suspected new IBD cases. If centres are delayed in assessing new IBD patients, a telephone triage system should be adopted to assess clinical urgency.",
            "cite_spans": [],
            "section": "New IBD patients ::: Changes to current primary and secondary care practices",
            "ref_spans": []
        },
        {
            "text": "Patients who may require hospitalisation will need to continue to be assessed in a timely manner. Consider the most appropriate location to do this that is away from COVID-19 assessment areas. Daily \u2018flare clinics\u2019 (virtual where possible) with limited numbers of patients who are at high risk of imminent hospitalisation should be considered. Where possible, limit visits to hospital and limit the patient journey around the hospital geographically.",
            "cite_spans": [],
            "section": "Urgent outpatient review ::: Changes to current primary and secondary care practices",
            "ref_spans": []
        },
        {
            "text": "Given the paucity of data regarding the effects of IBD medications on the course of COVID-19, contributing confirmed cases to the international registry (SECURE-IBD, https://covidibd.org) is encouraged.",
            "cite_spans": [],
            "section": "Therapy specific considerations",
            "ref_spans": []
        },
        {
            "text": "The BSG has provided separate guidance on endoscopy and COVID-19 (https://www.bsg.org.uk/covid-19-advice/). IBD surveillance procedures should be deferred. IBD disease assessment scopes will need to be carefully assessed for priority. Alternative methods of disease assessment, including the use of biomarkers, radiology and capsule endoscopy should be considered.",
            "cite_spans": [],
            "section": "Endoscopy ::: Service considerations",
            "ref_spans": []
        },
        {
            "text": "The capacity for outpatient imaging may be reduced. However, this should be discussed within individual hospitals. Access to different imaging modalities may vary during the pandemic and this may influence the choice of investigation for patients with IBD.",
            "cite_spans": [],
            "section": "Imaging ::: Service considerations",
            "ref_spans": []
        },
        {
            "text": "Routine elective operations have been deferred in most centres. Where possible, urgent management of perianal sepsis should be undertaken as a day case procedure. Complex IBD surgery should be deferred where possible and its timing should be reviewed regularly at multidisciplinary meetings. Emergency procedures (e.g. subtotal colectomy in acute severe UC, intestinal resection to control penetrating disease in CD) will continue as part of routine care. As with active disease, the choice of postoperative therapy to prevent recurrence will need to be considered in the context of the COVID-19 pandemic. If surgery is required for subacute obstructive symptoms, it may be possible to avoid or delay surgery by using partial or exclusive enteral nutrition regimens.21\n",
            "cite_spans": [
                {
                    "start": 766,
                    "end": 768,
                    "mention": "21",
                    "ref_id": "BIBREF13"
                }
            ],
            "section": "Surgery ::: Service considerations",
            "ref_spans": []
        },
        {
            "text": "The National Institute for Health Research (NIHR) and Chief Scientist Office (CSO) have produced guidance on the management of clinical trials which will be updated regularly (NIHR https://www.nihr.ac.uk/news/dhsc-issues-guidance-on-the-impact-on-covid-19-on-research-funded-or-supported-by-nihr/24469; CSO http://www.nhsresearchscotland.co.uk/news/covid-19---guidance-for-sponsors-sites-and-researchers). Many trials will have already been paused by their sponsors.",
            "cite_spans": [],
            "section": "Clinical trials ::: Service considerations",
            "ref_spans": []
        },
        {
            "text": "Where this has not happened, participant screening, recruitment and continuation (for participants already recruited) should be reviewed at the local level for appropriateness in the current clinical situation. The benefits of avoiding surgery and/or corticosteroids by receiving trial medication that may not be otherwise available must be balanced against the risk of face to face visits and the unknown effects of the investigational medicinal product on the course of COVID-19. Where possible, trial visits should occur virtually, and investigations that require hospital attendance should be postponed unless clinically important. Protocol amendments should be made to the relevant regulatory bodies, and advice should be sought from research and development directors promptly to protect participants, as formal approval may be significantly delayed. Blinded trials pose a particular concern; principal investigators should be prepared to unblind participants where the information will influence the participant\u2019s treatment or when assessment and management of coronavirus is being considered. In addition, patients who may be on a placebo medication that does not require self-isolation or social distancing should have this highlighted to them in case they wish to withdraw from a study. Sponsors should consider minimising the burden of administrative tasks while healthcare teams are stretched; many members of the research team are already being redeployed into direct clinical care.",
            "cite_spans": [],
            "section": "Clinical trials ::: Service considerations",
            "ref_spans": []
        },
        {
            "text": "Frontline staff with IBD should follow the same precautions as other IBD patients. However, given the high risk of exposure of frontline staff to SARS-CoV-2, it would be advisable that hospital teams consider utilising team members with IBD in roles where exposure is limited (i.e. telephone clinics as opposed to endoscopy lists and ward work), especially if that individual is at 'moderate\u2019 risk or has other comorbidity, in which case they should be supported in working from home if possible. If it is essential for them to work in a hospital environment, they should ensure they avoid close contact with other staff members and can maintain social distancing.",
            "cite_spans": [],
            "section": "Advice for NHS staff with IBD",
            "ref_spans": []
        },
        {
            "text": "The COVID-19 pandemic has posed unprecedented challenges to healthcare providers across the globe. The IBD community must continue to demonstrate adaptability in this rapidly moving field. Collaborative working is vital to ensure we gather as much knowledge as possible collectively, sharing ideas to provide the best outcomes for our patients as new evidence emerges.",
            "cite_spans": [],
            "section": "Conclusion",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "TABREF0": {
            "text": "Table 1: British Society of Gastroenterology inflammatory bowel disease COVID-19 risk grid: Stratification of risk of serious COVID-19 disease into highest, moderate and lowest risk categories for patients with inflammatory bowel disease\n",
            "type": "table"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology",
            "authors": [
                {
                    "first": "G-R",
                    "middle": [],
                    "last": "Jones",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Lyons",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Plevris",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Gut",
            "volume": "68",
            "issn": "",
            "pages": "1953-60",
            "other_ids": {
                "DOI": [
                    "10.1136/gutjnl-2019-318936"
                ]
            }
        },
        "BIBREF1": {
            "title": "Ibuprofen, paracetamol, and steam for patients with respiratory tract infections in primary care: pragmatic randomised factorial trial",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Little",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Moore",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Kelly",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "BMJ",
            "volume": "347",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1136/bmj.f6041"
                ]
            }
        },
        "BIBREF2": {
            "title": "Primary care randomised controlled trial of a tailored interactive website for the self-management of respiratory infections (Internet doctor)",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Little",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Stuart",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Andreou",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "BMJ Open",
            "volume": "6",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1136/bmjopen-2015-009769"
                ]
            }
        },
        "BIBREF3": {
            "title": "British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults",
            "authors": [
                {
                    "first": "CA",
                    "middle": [],
                    "last": "Lamb",
                    "suffix": ""
                },
                {
                    "first": "NA",
                    "middle": [],
                    "last": "Kennedy",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Raine",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Gut",
            "volume": "68",
            "issn": "",
            "pages": "s1-106",
            "other_ids": {
                "DOI": [
                    "10.1136/gutjnl-2019-318484"
                ]
            }
        },
        "BIBREF4": {
            "title": "SECURE-IBD registry: surveillance epidemiology of coronavirus (COVID-19) under research exclusion",
            "authors": [],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "IOIBD Update on COVID19 for Patients with Crohn\u2019s Disease and Ulcerative Colitis",
            "authors": [],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "1St interview COVID-19 ECCO Taskforce",
            "authors": [],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "Implications of COVID-19 for patients with pre-existing digestive diseases",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Mao",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Liang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Shen",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet Gastroenterol Hepatol",
            "volume": "",
            "issn": "",
            "pages": "426-8",
            "other_ids": {
                "DOI": [
                    "10.1016/S2468-1253(20)30076-5"
                ]
            }
        },
        "BIBREF8": {
            "title": "Protection of 318 inflammatory bowel disease patients from the outbreak and rapid spread of COVID-19 infection in Wuhan, China",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "An",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Ji",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Ren",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF9": {
            "title": "Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Wisniewski",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Kirchgesner",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Seksik",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "United Eur Gastroenterol J",
            "volume": "22",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1177/2050640619889763"
                ]
            }
        },
        "BIBREF10": {
            "title": "A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Naganuma",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Kunisaki",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Yoshimura",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "J Gastroenterol",
            "volume": "48",
            "issn": "",
            "pages": "595-600",
            "other_ids": {
                "DOI": [
                    "10.1007/s00535-012-0686-9"
                ]
            }
        },
        "BIBREF11": {
            "title": "A capture-recapture study of all-age IBD point prevalence",
            "authors": [
                {
                    "first": "GR",
                    "middle": [],
                    "last": "Jones",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Lyons",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Plevris",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Gut",
            "volume": "68",
            "issn": "",
            "pages": "A63-4",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF12": {
            "title": "Common infections in patients prescribed systemic glucocorticoids in primary care: a population-based cohort study",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Fardet",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Petersen",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Nazareth",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "PLoS Med",
            "volume": "13",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1371/journal.pmed.1002024"
                ]
            }
        },
        "BIBREF13": {
            "title": "Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for adults with Crohn's disease",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Heerasing",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Thompson",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Hendy",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Aliment Pharmacol Ther",
            "volume": "45",
            "issn": "",
            "pages": "660-9",
            "other_ids": {
                "DOI": [
                    "10.1111/apt.13934"
                ]
            }
        },
        "BIBREF14": {
            "title": "Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT\u2122 registry",
            "authors": [
                {
                    "first": "GR",
                    "middle": [],
                    "last": "Lichtenstein",
                    "suffix": ""
                },
                {
                    "first": "BG",
                    "middle": [],
                    "last": "Feagan",
                    "suffix": ""
                },
                {
                    "first": "RD",
                    "middle": [],
                    "last": "Cohen",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Am J Gastroenterol",
            "volume": "107",
            "issn": "",
            "pages": "1409-22",
            "other_ids": {
                "DOI": [
                    "10.1038/ajg.2012.218"
                ]
            }
        },
        "BIBREF15": {
            "title": "Clinical characteristics of coronavirus disease 2019 in China",
            "authors": [
                {
                    "first": "W-jie",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "Z-yi",
                    "middle": [],
                    "last": "Ni",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1056/NEJMoa2002032"
                ]
            }
        },
        "BIBREF16": {
            "title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "1054-62",
            "other_ids": {
                "DOI": [
                    "10.1016/S0140-6736(20)30566-3"
                ]
            }
        },
        "BIBREF17": {
            "title": "The COVID-19 Task force of the Department of Infectious Diseases and the IT Service Istituto Superiore di Sanit",
            "authors": [],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF18": {
            "title": "Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zheng",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Gou",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Int J Infect Dis",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1016/j.ijid.2020.03.017"
                ]
            }
        },
        "BIBREF19": {
            "title": "COVID-19 and smoking: a systematic review of the evidence",
            "authors": [
                {
                    "first": "CI",
                    "middle": [],
                    "last": "Vardavas",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Nikitara",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Tob Induc Dis",
            "volume": "18",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.18332/tid/119324"
                ]
            }
        },
        "BIBREF20": {
            "title": "COVID-19: the gendered impacts of the outbreak",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Wenham",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Smith",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Morgan",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "846-8",
            "other_ids": {
                "DOI": [
                    "10.1016/S0140-6736(20)30526-2"
                ]
            }
        }
    }
}